Featured Research

from universities, journals, and other organizations

Imaging techniques may help predict response to head and neck cancer treatment

Date:
November 23, 2009
Source:
JAMA and Archives Journals
Summary:
A combination of imaging tests conducted six to eight weeks after patients complete chemoradiotherapy for head and neck cancer may help identify patients who will respond to treatment and those who will require surgical follow-up, according to a new study.

A combination of imaging tests conducted six to eight weeks after patients complete chemoradiotherapy for head and neck cancer may help identify patients who will respond to treatment and those who will require surgical follow-up, according to a report in the November issue of Archives of Otolaryngology-Head & Neck Surgery, one of the JAMA/Archives journals.

During the past two decades, chemoradiotherapy -- combining chemotherapy and radiation treatments -- has become important in helping preserve organs while treating advanced head and neck cancers, according to background information in the article. "These non-surgical approaches produce an excellent response at the primary tumor site and cervical lymph nodes resulting in high rates of locoregional disease control," the authors write. "Accurate and timely assessment of disease response at the primary tumor site and cervical lymph nodes after chemoradiotherapy is essential to detect residual disease, to direct surgical salvage and to prevent tumor recurrence."

James P. Malone, M.D., of the Southern Illinois School of Medicine, Springfield, and colleagues analyzed 31 patients with advanced-stage head and neck cancer who were treated with chemoradiotherapy between 2004 and 2006. All patients underwent combined positron emission tomography and computed tomography (PET-CT) to detect evidence of persistent tumors six to eight weeks after the completion of treatment and then were tracked for a median (midpoint) of 24 months.

Assessing the response of the tumor to treatment with PET-CT had a sensitivity (rate of true positives) of 83 percent, specificity (rate of true negatives) of 54 percent, positive predictive value (probability that patients who test positive have the disease) of 31 percent and negative predictive value (probability that patients who test negative do not have the disease) of 92 percent.

In the 21 patients (78 percent) whose disease had spread to surrounding lymph nodes before treatment, sensitivity was 75 percent; specificity, more than 94 percent; positive predictive value, more than 75 percent; and negative predictive value, 94 percent. For the ten (32 percent) whose cancer was located in the neck only, specificity was 92 percent and negative predictive value more than 92 percent.

"On the basis of this study, PET-CT performed six to eight weeks after the completion of intra-arterial chemoradiotherapy for advanced squamous cell carcinoma of the head and neck is a valuable tool for measuring treatment response and facilitating clinical decision making," they conclude. "In addition to early prediction of treatment response, PET-CT provides early detection of distant metastases, which permits earlier intervention in patients with distant disease. Further investigations of PET-CT in homogenously treated patient populations with consistent timing of post-treatment scans are necessary to more clearly elucidate the role of this imaging modality in the management of advanced squamous cell carcinoma of the head and neck."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Malone et al. Early Prediction of Response to Chemoradiotherapy for Head and Neck Cancer: Reliability of Restaging With Combined Positron Emission Tomography and Computed Tomography. Archives of Otolaryngology - Head and Neck Surgery, 2009; 135 (11): 1119 DOI: 10.1001/archoto.2009.152

Cite This Page:

JAMA and Archives Journals. "Imaging techniques may help predict response to head and neck cancer treatment." ScienceDaily. ScienceDaily, 23 November 2009. <www.sciencedaily.com/releases/2009/11/091116165631.htm>.
JAMA and Archives Journals. (2009, November 23). Imaging techniques may help predict response to head and neck cancer treatment. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/11/091116165631.htm
JAMA and Archives Journals. "Imaging techniques may help predict response to head and neck cancer treatment." ScienceDaily. www.sciencedaily.com/releases/2009/11/091116165631.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins